Albumin: a comprehensive review and practical guideline for clinical use

• Published in: European journal of clinical pharmacology 2024-08, Vol.80 (8), p.1151-1169
• Main Authors: Abedi, Farshad, Zarei, Batool, Elyasi, Sepideh
• Format: Article
• Language: English
• Subjects: Albumin; Albumins - administration & dosage; Albumins - therapeutic use; Biomedical and Life Sciences; Biomedicine; Cirrhosis; Edema; Fluid Therapy - methods; Humans; Hypoalbuminemia - therapy; Hyponatremia; Hypotension; Liver cirrhosis; Liver diseases; Ovarian hyperstimulation syndrome; Peritonitis; Pharmacology/Toxicology; Plasmapheresis; Practice Guidelines as Topic; Respiratory distress syndrome; Sepsis; Septic shock; Toxic epidermal necrolysis; Traumatic brain injury
• ISSN: 0031-6970; 1432-1041; 1432-1041
• DOI: 10.1007/s00228-024-03664-y

Purpose Nowadays, it is largely accepted that albumin should not be used in hypoalbuminemia or for nutritional purpose. The most discussed indication of albumin at present is the resuscitation in shock states, especially distributive shocks such as septic shock. The main evidence-based indication is also liver disease. In this review, we provided updated evidence-based instruction for definite and potential indications of albumin administration in clinical practice, with appropriate dosing and duration. Methods Data collection was carried out until November 2023 by search of electronic databases including PubMed, Google Scholar, Scopus, and Web of Science. GRADE system has been used to determine the quality of evidence and strength of recommendations for each albumin indication. Results A total of 165 relevant studies were included in this review. Fluid replacement in plasmapheresis and liver diseases, including hepatorenal syndrome, spontaneous bacterial peritonitis, and large-volume paracentesis, have a moderate to high quality of evidence and a strong recommendation for administering albumin. Moreover, albumin is used as a second-line and adjunctive to crystalloids for fluid resuscitation in hypovolemic shock, sepsis and septic shock, severe burns, toxic epidermal necrolysis, intradialytic hypotension, ovarian hyperstimulation syndrome, major surgery, non-traumatic brain injury, extracorporeal membrane oxygenation, acute respiratory distress syndrome, and severe and refractory edema with hypoalbuminemia has a low to moderate quality of evidence and weak recommendation to use. Also, in modest volume paracentesis, severe hyponatremia in cirrhosis has a low to moderate quality of evidence and a weak recommendation. Conclusion Albumin administration is most indicated in management of cirrhosis complications. Fluid resuscitation or treatment of severe and refractory edema, especially in patients with hypoalbuminemia and not responding to other treatments, is another rational use for albumin. Implementation of evidence-based guidelines in hospitals can be an effective measure to reduce inappropriate uses of albumin.